

Syn-One Test[®]



DIAGNOSE NEURODEGENERATIVE DISORDERS WITH GREATER PRECISION

Syn-One Provides Reliable and Early Detection of Phosphorylated Alpha-Synuclein Through a Simple Skin Biopsy^{1,2,3}

The Skin Is a Unique Window Into the Central Nervous System

By detecting abnormal alpha-synuclein in nerves of the skin, Syn-One helps diagnose the following synucleinopathies at different stages of disease progression¹:

- Parkinson's disease
- Dementia with Lewy bodies
- Multiple system atrophy
- Pure autonomic failure
- REM sleep behavior disorder*



1. Gibbons CH et al. Skin biopsy detection of p- α -synuclein in patients with synucleinopathies. *JAMA*. 2024;331(15):1298-306.

2. Levine T et al. Syn-Sleep study: cutaneous p- α -synuclein in RBD. *SLEEP* 2025, Seattle, WA; Jun 8-11, 2025.

3. Gibbons C et al. Syn-D study: cutaneous p- α -synuclein & blood P-tau217 in MCI. *Neurology*. 2025;104(7 Suppl 1).

* REM sleep behavior disorder (RBD) is considered a prodromal synucleinopathy. This is based on interim baseline results from CND Life Sciences' NIH-sponsored, multicenter, prospective, blinded study of 80 patients diagnosed with idiopathic RBD.

The Answers Clinicians and Patients Need

Results from the Syn-One Test, along with a complete health history and clinical features, can help clinicians advise their patients on next steps. In fact, in a recent study, 78% of patients had a change in their clinical care as a result of the test, and the original diagnosis was changed in almost two-thirds of patients tested.

This finding is based on a retrospective chart review of changes in diagnosis and medical management of patients with suspected synucleinopathies following administration of the Syn-One Test.⁴

4. Isaacson JR, Freeman R, Gibbons CH. Clinical utility of synuclein skin biopsy in the diagnosis and evaluation of synucleinopathies. *Front Neurol.* Dec 18;15:1510796. Doi: 10.3389/fneur.2024.1510796



“This test result was a defining moment. We knew from that point forward what I was dealing with.”

— Feedback from Syn-One Test patient survey

FOUR DIAGNOSTIC FEATURES OF SYN-ONE

Outcome Measure	Type of Stain	Disease State
Phosphorylated Alpha-Synuclein (P-SYN)	P-SYN Antibody with Immunofluorescence	Synucleinopathy (PD, DLB, MSA, PAF, RBD)
Intraepidermal Nerve Fiber Density (IENFD)	PGP 9.5 Antibody with Immunofluorescence	Peripheral Nerve Degeneration
Amyloid	Congo Red	Amyloidosis
Skin Morphology	Hematoxylin and Eosin (H&E)	Benign or Malignant Pathologies



Expert Support Beyond the Test

CND Life Sciences supports clinicians, practices, and patients with:

- A Clinical Services team ready to assist with questions related to Syn-One
- Access to CND neurologists with expertise in pathology interpretation
- Patient access and billing specialists to help determine benefits and coverage
- Patient resources and information related to Syn-One

Learn more at cndlifesciences.com